SORBITOL-MANNITOL
Clinical safety rating
safeOther diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.
Sorbitol and mannitol are sugar alcohols that act as osmotic diuretics. They are filtered by the glomerulus but not reabsorbed, increasing osmotic pressure in the tubular lumen, thereby reducing water reabsorption and promoting diuresis. They also increase intraocular pressure and decrease intracranial pressure by drawing water from tissues into the bloodstream.
| Metabolism | Both sorbitol and mannitol are not metabolized to a significant extent. They are primarily excreted unchanged by the kidney. Minor metabolism of sorbitol to fructose in the liver may occur. |
| Excretion | Primarily renal excretion as unchanged drug; >90% eliminated via urine within 24 hours. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours; may be prolonged in renal impairment. |
| Protein binding | Not significantly protein bound (<5%). |
| Volume of Distribution | Vd approximately 0.3-0.5 L/kg; distributes primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is low (approximately 10-20%) due to poor absorption; intravenously, bioavailability is 100%. |
| Onset of Action | Intravenous administration: osmotic diuresis begins within 1-3 hours after infusion; oral administration: cathartic effect occurs within 0.5-3 hours. |
| Duration of Action | Intravenous: diuretic effect lasts 4-6 hours; oral: cathartic effect lasts 3-6 hours. |
| Molecular Weight | 182.17 |
Osmotic diuretic; 50-100 g (as 25% solution) IV over 30-60 minutes, may repeat every 6-12 hours as needed; maximum 200 g/day.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in anuria and severe renal impairment (GFR < 20 mL/min). Use with caution if GFR 20-50 mL/min, reduce dose by 50% and monitor serum osmolality. |
| Liver impairment | No specific adjustment required; use with caution in severe hepatic impairment due to risk of volume overload and electrolyte disturbances. |
| Pediatric use | 0.5-2 g/kg (as 25% solution) IV over 30-60 minutes, may repeat every 6-12 hours; maximum 2 g/kg per dose. |
| Geriatric use | Start at lowest effective dose (25-50 g) and titrate; monitor renal function, electrolytes, and volume status closely due to increased risk of renal impairment and fluid overload. |
| 1st trimester | No adequate studies; consider risk vs benefit. Use only if clearly needed. |
| 2nd trimester | No adequate studies; consider risk vs benefit. Use only if clearly needed. |
| 3rd trimester | Avoid use near term due to potential osmotic effects and dehydration in neonate. |
Clinical note
Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.
| FDA category | Animal |
| Placental transfer | Yes, sorbitol and mannitol cross the placenta; mannitol detected in fetal blood at concentrations similar to maternal levels. |
| Breastfeeding | Not recommended due to potential for osmotic diarrhea and electrolyte imbalance in infant. Limited data suggest excretion into breast milk is likely minimal, but safety not established. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Sorbitol and mannitol are hexahydric alcohols used as osmotic diuretics. Limited human data; animal studies show no teratogenicity at therapeutic doses. Inadvertent intravenous use in pregnancy may cause maternal electrolyte imbalance, dehydration, and potential fetal compromise from altered placental perfusion. First trimester: no established teratogenic risk. Second and third trimesters: risk of maternal hypotension and fetal hypoxia if rapid administration; avoid unless clearly needed. Consider alternative agents if risk-benefit justified. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, serum electrolytes, osmolality, and fluid balance before, during, and after administration. Fetal heart rate monitoring during infusion if viable pregnancy. Urine output assessment to avoid over-diuresis. Signs of pulmonary edema or congestive heart failure in mother. |
| Fertility Effects | No known negative impact on human fertility. Animal studies show no adverse effects on reproduction. However, chronic use in conditions like glaucoma (sorbitol) may be theoretical but no established clinical effect. |
■ FDA Black Box Warning
None
| Common Effects | edema |
| Serious Effects |
AnuriaSevere dehydrationKnown hypersensitivity to sorbitol or mannitolIntracranial hemorrhage (except during craniotomy)
| Precautions | Monitor serum electrolytes and renal function; risk of hypernatremia or hyponatremia, May worsen heart failure due to increased intravascular volume, Use caution in patients with severe renal impairment or anuria, Intravenous administration of mannitol can cause crystalluria, Sorbitol in dialysis solutions may cause hyperglycemia in diabetic patients |
| Food/Dietary | Avoid concurrent ingestion of high-sugar foods as sorbitol can cause osmotic diarrhea. No significant food interactions with mannitol. Maintain adequate fluid intake during use. |
| Clinical Pearls | Sorbitol-mannitol is a hyperosmolar laxative and diagnostic aid. Monitor for metabolic acidosis and electrolyte disturbances, especially in renal impairment. In colonoscopy prep, ensure adequate hydration to prevent hypotension. Contraindicated in anuria, congestive heart failure, and gastrointestinal obstruction. |
| Patient Advice | Take with plenty of water to prevent dehydration. · May cause diarrhea, cramping, and electrolyte imbalance; report severe symptoms. · Avoid use if you have kidney disease, heart failure, or bowel obstruction. · Do not use as a daily laxative; prolonged use may cause dependence. |
Loading safety data…